Adell Harriman & Carpenter Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,984 shares of the biopharmaceutical company’s stock after selling 1,250 shares during the period. Adell Harriman & Carpenter Inc.’s holdings in Gilead Sciences were worth $644,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of GILD. FMR LLC boosted its holdings in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Macquarie Group Ltd. boosted its holdings in Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares during the period. Vanguard Group Inc. boosted its holdings in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Northern Trust Corp boosted its holdings in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares during the period. Finally, Toronto Dominion Bank boosted its holdings in Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after acquiring an additional 75,364 shares during the period. Hedge funds and other institutional investors own 77.96% of the company’s stock.
A number of equities research analysts have issued reports on the stock. Barclays restated an “overweight” rating and set a $95.00 price target (up from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Royal Bank of Canada reaffirmed a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research report on Friday, February 23rd. Finally, Leerink Swann reaffirmed a “market perform” rating and set a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $88.61.
Gilead Sciences, Inc. (GILD) opened at $79.74 on Friday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The stock has a market cap of $104,760.00, a PE ratio of 10.37, a P/E/G ratio of -1.83 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.70 earnings per share. analysts expect that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is presently 29.65%.
In other news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP James R. Meyers sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the sale, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 430,268 shares of company stock valued at $34,074,395. Company insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/18/adell-harriman-carpenter-inc-sells-1250-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.